Longbow Capital
Longbow Capital is a private equity investment management firm based in Calgary, Alberta, established in 1997. The company specializes in investments within the energy and technology sectors, with a particular emphasis on promoting efficient, cost-effective, and environmentally responsible energy solutions. In 2022, Longbow Capital launched the Energy Transition Fund, aimed at supporting growth and expansion in the energy sector and business-to-business services. The fund primarily targets investment opportunities in both the United States and Canada, reflecting Longbow's commitment to advancing sustainable energy initiatives.
Clir Renewables Inc. develops cloud based renewable energy asset management and reporting software. Its software-as-a-service platform assists asset managers and owners in enhancing annual energy production and domain expertise, monitoring asset health, and managing financial and technical risk. The company was founded in 2016 and is headquartered in Vancouver, Canada with an additional office in Glasgow, United Kingdom.
VoltaGrid LLC, based in Bellaire, Texas, operates in the energy sector, focusing on advanced energy management and generation solutions. Founded in 2020 and previously known as Nexgrid Technologies LLC, the company has developed a portable and scalable power platform that integrates natural gas with grid power. This innovative system is designed to enhance power quality and reliability while enabling clients in industries such as pressure pumping, remote mining, utilities, and distributed generation to achieve significant reductions in emissions and fuel consumption. VoltaGrid's offerings aim to provide intelligent and clean energy solutions to meet the evolving needs of its customers.
Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry.
Service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.